MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation

TSX:MDP • CA58410Q2036

Current stock price

3.9 CAD
-0.07 (-1.76%)
Last:

This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. MDP.CA Profitability Analysis

1.1 Basic Checks

  • In the past year MDP has reported negative net income.
  • MDP had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
  • In multiple years MDP reported negative operating cash flow during the last 5 years.
MDP.CA Yearly Net Income VS EBIT VS OCF VS FCFMDP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

1.2 Ratios

  • The Return On Assets of MDP (-0.18%) is better than 70.97% of its industry peers.
  • With a decent Return On Equity value of -0.52%, MDP is doing good in the industry, outperforming 74.19% of the companies in the same industry.
  • MDP's Return On Invested Capital of 3.02% is fine compared to the rest of the industry. MDP outperforms 67.74% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 8.64%.
  • The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROIC 3.02%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
MDP.CA Yearly ROA, ROE, ROICMDP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • Looking at the Operating Margin, with a value of 3.91%, MDP is in the better half of the industry, outperforming 70.97% of the companies in the same industry.
  • MDP has a Gross Margin of 53.87%. This is amongst the best in the industry. MDP outperforms 80.65% of its industry peers.
  • MDP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.91%
PM (TTM) N/A
GM 53.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
MDP.CA Yearly Profit, Operating, Gross MarginsMDP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDP.CA Health Analysis

2.1 Basic Checks

  • MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • MDP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MDP has been increased compared to 5 years ago.
  • The debt/assets ratio for MDP has been reduced compared to a year ago.
MDP.CA Yearly Shares OutstandingMDP.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MDP.CA Yearly Total Debt VS Total AssetsMDP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 0.77, we must say that MDP is in the distress zone and has some risk of bankruptcy.
  • MDP has a Altman-Z score (0.77) which is in line with its industry peers.
  • The Debt to FCF ratio of MDP is 1.48, which is an excellent value as it means it would take MDP, only 1.48 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.48, MDP belongs to the top of the industry, outperforming 90.32% of the companies in the same industry.
  • MDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of MDP (0.35) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Altman-Z 0.77
ROIC/WACC0.33
WACC9.19%
MDP.CA Yearly LT Debt VS Equity VS FCFMDP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • MDP has a Current Ratio of 1.12. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of MDP (1.12) is worse than 80.65% of its industry peers.
  • A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
  • The Quick ratio of MDP (0.62) is worse than 83.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.62
MDP.CA Yearly Current Assets VS Current LiabilitesMDP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDP.CA Growth Analysis

3.1 Past

  • The earnings per share for MDP have decreased strongly by -112.14% in the last year.
  • Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -9.23% in the last year.
  • Measured over the past years, MDP shows a small growth in Revenue. The Revenue has been growing by 7.82% on average per year.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%

3.2 Future

  • Based on estimates for the next years, MDP will show a very strong growth in Earnings Per Share. The EPS will grow by 53.29% on average per year.
  • Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.80% on average per year.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDP.CA Yearly Revenue VS EstimatesMDP.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
MDP.CA Yearly EPS VS EstimatesMDP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. MDP.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • MDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 8.81, the valuation of MDP can be described as reasonable.
  • 83.87% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
  • MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.81
MDP.CA Price Earnings VS Forward Price EarningsMDP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaper than 80.65% of the companies in the same industry.
  • MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 87.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.36
EV/EBITDA 7.66
MDP.CA Per share dataMDP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MDP's earnings are expected to grow with 109.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDP.CA Dividend Analysis

5.1 Amount

  • No dividends for MDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDP.CA Fundamentals: All Metrics, Ratios and Statistics

MEDEXUS PHARMACEUTICALS INC

TSX:MDP (4/21/2026, 7:00:00 PM)

3.9

-0.07 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)N/A
Inst Owners1.21%
Inst Owner ChangeN/A
Ins Owners7.73%
Ins Owner ChangeN/A
Market Cap125.97M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.48 (91.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)6.47%
PT rev (3m)18.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.81
P/S 0.93
P/FCF 5.36
P/OCF 5.3
P/B 1.76
P/tB N/A
EV/EBITDA 7.66
EPS(TTM)-0.02
EYN/A
EPS(NY)0.44
Fwd EY11.35%
FCF(TTM)0.73
FCFY18.65%
OCF(TTM)0.74
OCFY18.88%
SpS4.22
BVpS2.21
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROCE 4.2%
ROIC 3.02%
ROICexc 3.61%
ROICexgc 107.26%
OM 3.91%
PM (TTM) N/A
GM 53.87%
FCFM 17.26%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Debt/EBITDA 1.33
Cap/Depr 2.1%
Cap/Sales 0.21%
Interest Coverage 1.57
Cash Conversion 127.65%
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.62
Altman-Z 0.77
F-Score5
WACC9.19%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A

MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.


What is the valuation status for MDP stock?

ChartMill assigns a valuation rating of 5 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.


What is the profitability of MDP stock?

MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.


How financially healthy is MEDEXUS PHARMACEUTICALS INC?

The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.